Table 2

Comparison of the antimicrobial susceptibility of community-acquired (CA) and healthcare-associated (HCA)Klebsiella pneumoniaebloodstream infection (KpBSI)
Antibiotics CA-KpBSI (n = 240) HCA-KpBSI (n = 313) p
(Non-susceptible/T (%)) (Non-susceptible/T (%))
Ciprofloxacin 12/240 (5.0) 36/313 (11.5) 0.007
Extended-spectrum cephalosporin 8/240 (3.3) 29/313 (9.3) 0.006
  Cefotaxime 8/240 (3.3) 25/313 (8.0) 0.022
  Ceftazidime 6/240 (2.5) 25/313 (8.0) 0.005
ESBL-productiona 2/237 (0.8) 16/310 (5.2) 0.006
Piperacillin plus tazobactam 6/239 (2.5) 19/311 (6.1) 0.045
Aztreonam 5/175 (2.9) 26/253 (11.1) 0.004
Imipenem 1/240 (0.4) 1/313 (0.3) 1.000
Amikacin 7/240 (2.9) 17/313 (5.4) 0.150
Gentamicin 6/240 (2.5) 22/313 (7.0) 0.016
Tobramycin 7/177 (4.0) 26/253 (10.3) 0.015

Data indicate number of non-susceptible isolates/total number of tested isolates (%).

T, total number of tested isolates; ESBL, extended-spectrum beta-lactamase.

a 5 isolates among the CA-KpBSI were available for ESBL confirmatory tests and 14 among the HCA-KpBSI.

Jung et al.

Jung et al. BMC Infectious Diseases 2012 12:239   doi:10.1186/1471-2334-12-239

Open Data